Daniel Tatosian

752 total citations
26 papers, 498 citations indexed

About

Daniel Tatosian is a scholar working on Endocrinology, Diabetes and Metabolism, Oncology and Molecular Biology. According to data from OpenAlex, Daniel Tatosian has authored 26 papers receiving a total of 498 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Endocrinology, Diabetes and Metabolism, 8 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Daniel Tatosian's work include Diabetes Treatment and Management (9 papers), Peptidase Inhibition and Analysis (5 papers) and Nigella sativa pharmacological applications (4 papers). Daniel Tatosian is often cited by papers focused on Diabetes Treatment and Management (9 papers), Peptidase Inhibition and Analysis (5 papers) and Nigella sativa pharmacological applications (4 papers). Daniel Tatosian collaborates with scholars based in United States, Belgium and Japan. Daniel Tatosian's co-authors include Michael L. Shuler, Eunkyung Kauh, Donghyun Kim, Carol Addy, Pradeep Sharma, Xiaoyan Chu, Jan Snoeys, Jashvant D. Unadkat, Pär Matsson and Yingying Guo and has published in prestigious journals such as Gastroenterology, Optics Letters and Journal of Pharmaceutical Sciences.

In The Last Decade

Daniel Tatosian

25 papers receiving 483 citations

Peers

Daniel Tatosian
Zhuang Miao China
Lai Wang China
Tomoya Yasujima Japan
Emi Kamiyama Japan
Sangeeta Raje United States
Yusheng Zhu United States
Raquel F. Reinoso Spain
Kevin Dykstra United States
Sumihiko Okuyama Japan
Jing Ning China
Zhuang Miao China
Daniel Tatosian
Citations per year, relative to Daniel Tatosian Daniel Tatosian (= 1×) peers Zhuang Miao

Countries citing papers authored by Daniel Tatosian

Since Specialization
Citations

This map shows the geographic impact of Daniel Tatosian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Tatosian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Tatosian more than expected).

Fields of papers citing papers by Daniel Tatosian

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Tatosian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Tatosian. The network helps show where Daniel Tatosian may publish in the future.

Co-authorship network of co-authors of Daniel Tatosian

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Tatosian. A scholar is included among the top collaborators of Daniel Tatosian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Tatosian. Daniel Tatosian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Regueiro, Miguel, Britta Siegmund, Sara N. Horst, et al.. (2024). Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis. Inflammatory Bowel Diseases. 31(4). 1010–1017.
2.
Naismith, Robert T., Jeffrey A. Cohen, Amit Bar‐Or, et al.. (2023). Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial. Multiple Sclerosis Journal. 30(2). 177–183. 3 indexed citations
3.
Shen, Jun, Daniel Tatosian, Nathan S. Teuscher, et al.. (2022). POPULATION PHARMACOKINETICS OF OZANIMOD AND ACTIVE METABOLITE CC112273 IN PATIENTS WITH ULCERATIVE COLITIS. Gastroenterology. 162(3). S17–S18. 1 indexed citations
4.
Shen, Jun, Daniel Tatosian, Nathan S. Teuscher, et al.. (2022). POPULATION PHARMACOKINETICS OF OZANIMOD AND ACTIVE METABOLITE CC112273 IN PATIENTS WITH ULCERATIVE COLITIS. Inflammatory Bowel Diseases. 28(Supplement_1). S17–S18. 1 indexed citations
5.
Ye, Ying, Allison Gaudy, Michael A. Thomas, et al.. (2022). Safety, Pharmacokinetics, and Pharmacodynamics of CC‐90001 (BMS‐986360), a c‐Jun N‐terminal Kinase Inhibitor, in Phase 1 Studies in Healthy Participants. Clinical Pharmacology in Drug Development. 11(12). 1394–1404. 4 indexed citations
6.
Tatosian, Daniel, Jim X Shen, Nathan S. Teuscher, et al.. (2021). P315 Population pharmacokinetics and pharmacodynamics of ozanimod in ulcerative colitis. Journal of Crohn s and Colitis. 15(Supplement_1). S341–S342. 1 indexed citations
7.
Jain, Lokesh, Anne Chain, Daniel Tatosian, et al.. (2019). Pharmacokinetic–pharmacodynamic (dipeptidyl peptidase‐4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once‐weekly administered omarigliptin. British Journal of Clinical Pharmacology. 85(12). 2759–2771. 7 indexed citations
8.
Guo, Yingying, Xiaoyan Chu, Neil Parrott, et al.. (2018). Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches. Clinical Pharmacology & Therapeutics. 104(5). 865–889. 88 indexed citations
9.
10.
11.
Addy, Carol, Daniel Tatosian, Isaias Noel Gendrano, et al.. (2016). Effects of Age, Sex, and Obesity on the Single‐Dose Pharmacokinetics of Omarigliptin in Healthy Subjects. Clinical Pharmacology in Drug Development. 5(5). 374–382. 7 indexed citations
12.
Friedman, Evan, Carol Addy, Daniel Tatosian, et al.. (2016). Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once‐weekly dipeptidyl peptidase‐4 inhibitor, in healthy Japanese men. Journal of Diabetes Investigation. 8(1). 84–92. 21 indexed citations
13.
Krishna, Rajesh, Carol Addy, Daniel Tatosian, et al.. (2016). Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once‐Weekly Dipeptidyl Peptidase‐4 (DPP‐4) Inhibitor, After Single and Multiple Doses in Healthy Subjects. The Journal of Clinical Pharmacology. 56(12). 1528–1537. 29 indexed citations
14.
Young, Katherine, Mary Motyl, & Daniel Tatosian. (2016). Effect of Imipenem-Relebactam on Sub-types of KPC in Klebsiella pneumoniae. Open Forum Infectious Diseases. 3(suppl_1). 1 indexed citations
15.
Mitra, Amitava, Brad Roadcap, Christine Mestre, et al.. (2015). Use of Minipig Skin Biopsy Model as an Innovative Tool to Design Topical Formulation to Achieve Desired Pharmacokinetics in Humans. Journal of Pharmaceutical Sciences. 104(5). 1701–1708. 12 indexed citations
16.
Tatosian, Daniel, Ying Guo, Andrea Schaeffer, et al.. (2013). Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin. Diabetes Therapy. 4(2). 431–442. 38 indexed citations
17.
Murphy, M. Gail, et al.. (2012). A Single‐Dose Bioequivalence and Food Effect Study With Aprepitant and Fosaprepitant Dimeglumine in Healthy Young Adult Subjects. Clinical Pharmacology in Drug Development. 1(3). 93–101. 10 indexed citations
18.
Tatosian, Daniel & Michael L. Shuler. (2008). A novel system for evaluation of drug mixtures for potential efficacy in treating multidrug resistant cancers. Biotechnology and Bioengineering. 103(1). 187–198. 111 indexed citations
19.
Sung, Jong Hwan, et al.. (2007). Real‐time fluorescence detection of multiple microscale cell culture analog devices in situ. Cytometry Part A. 71A(10). 857–865. 26 indexed citations
20.
Tatosian, Daniel, Michael L. Shuler, & Donghyun Kim. (2005). Portable in situ fluorescence cytometry of microscale cell-based assays. Optics Letters. 30(13). 1689–1689. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhuang Miao Breakdown of academic impact, for papers by Lai Wang Breakdown of academic impact, for papers by Tomoya Yasujima Breakdown of academic impact, for papers by Emi Kamiyama Breakdown of academic impact, for papers by Sangeeta Raje Breakdown of academic impact, for papers by Yusheng Zhu Breakdown of academic impact, for papers by Raquel F. Reinoso Breakdown of academic impact, for papers by Kevin Dykstra Breakdown of academic impact, for papers by Sumihiko Okuyama Breakdown of academic impact, for papers by Jing Ning
Rankless by CCL
2026